Bioequivalence and Bioavailability Forum 20:38 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Product-specific advice (Benserazide+levo­dopa) [Design Issues]

posted by Mauricio Sampaio - Brazil, 2018-01-10 16:22  - Posting: # 18162
Views: 840

(edited by Mauricio Sampaio on 2018-01-10 16:35)

Dear Mikalai,

First of all we need remember what is the Benserazide and its function in this fixed combination.

Benserazide is a DOPA decarboxylase inhibitor, which is unable to cross the blood–brain barrier. It is a peripherally-acting aromatic L-amino acid decarboxylase. So, Benserazide is a lyase enzyme and catalyzes several different decarboxylation reactions.

Benserazide inhibits the peripheral conversion of l-dopa into dopamine. This allows dopamine to build up solely in the brain and the adverse effects caused by peripheral dopamine, such as vasoconstriction, nausea, and arrhythmia, are minimized.

» We approached several experts to write a protocol of the study. However, they informed us that there is a substantial lack of information on the pharmacokinetics of benserazide to finalize the protocol.

I disagree!!! :no:

Benserazide show a rapid increase and rapid decrease in its plasma concentration and the pharmacokinetics of systemic benserazide does not seem to contribute to the elimination of levodopa. (look the references below)

Therefore, Benserazide has non significant therapeutic effect on its own, and its effect occurs synergically in combination with levodopa (used in the management of Parkinson's disease). If Benserazide (isolated/alone) has not therapeutic effect, why I need to quantify in bioequivalence study? Forget quantification of Benzeraside! :vomit:

In conclusion, your plan (the best design) to conduct the bioequivalence study of levodopa and benserazide must quantify only levodopa and its metabolite 3-O-methyldopa. Why ? :confused: Because, 3-O-methyldopa is one of the most important active metabolites of L-DOPA and its half-life (15 hours approximately) is longer than L-DOPA's half-life, which is about one hour. This means that the accumulate of 3-O-methyldopa in plasma and in the brain help chronic patients suffering from Parkinson's disease. :cool:

Pay attention :waving:: Both components (levodopa and its metabolite 3-O-methyldopa) need reach the target of bioequivalence acceptance criteria.




Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,783 posts in 4,003 threads, 1,258 registered users;
online 12 (0 registered, 12 guests [including 8 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

BEBAC Ing. Helmut Schütz